Results 211 to 220 of about 1,252,989 (357)

In Situ Engineering of Tumor Cells as Self‐Sustaining cDC1 Programming Factories for Effective Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
The fused EV platform AS16‐EL@MPLA/p‐FX reprograms tumor cells into cytokine‐producing factories that continuously secrete XCL1 and FLT3L to recruit and differentiate cDC1s, while embedded MPLA activates them through TLR4 signaling and AS16 prevents their exhaustion, thereby enhancing antitumor immunity and establishing durable immune memory against ...
Shuiling Jin   +16 more
wiley   +1 more source

Mesenchymal Stem Cell‐Derived Extracellular Vesicles Modulate the Course of Peritoneal Inflammation Through Metabolic and Epigenetic Regulation

open access: yesAdvanced Science, EarlyView.
MSC‐EVs alleviate peritoneal inflammation and fibrogenesis by disrupting the H3K18la‐CCL2 axis and crosstalk between mesothelial cells and Ly6c2⁺ macrophages. Model cartoons are constructed using the Biorender website (https://www.biorender.com/), and a usage license is obtained. Abstract Peritoneal dialysis (PD), as a renal replacement therapy, relies
Qiang Huang   +12 more
wiley   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Lymph Node Trabecula

open access: hybrid, 2020
National Cancer Institute
openalex   +1 more source

Home - About - Disclaimer - Privacy